{
  "docId": "019de076-b5af-740f-a5f5-cc716fe64761",
  "docSlug": "e5f34198aff4080f2687fe569caff4c0",
  "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
  "authorId": "neurosense-therapeutics",
  "authorName": "NeuroSense Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 33,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "comparison_table",
  "function": "cite_precedent",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a case study to validate the business model of combination therapies.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/23",
  "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761",
  "deckJsonHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761.json",
  "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.64,
        "y": 0.22
      },
      "kind": "list",
      "text": "Successful combination strategies in neurology:\nAlzheimer's: Donepezil + Memantine\nParkinson's: Entacapone + levodopa/carbidopa\nALS: Sodium Phenybuterate + Taurursodiol\nSMA: Onasemnogene + Nusinersen\nEpilepsy: Lamotrigine + Valproate/Carbamazepine",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b3ac9c02-5960-44f1-8b7e-24e1b5e3d545",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.55,
        "x": 0.06,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "Case Study: Amylyx (NASDAQ: AMLX)\nMarket Cap: ~ $1 B (Jan 2024)\nDrug: ALS Combination Therapy of generic + supplement\nPrice: $158,000/ year\nEstimated 2026 Sales: $1.1B/ year\nThe FDA approved Amylyx's drug, AMX0035 (Relyvrio), in September 2022 after Phase 2 clinical trial attenuated diseases progression (ALSFRS-R) by 25% when compared to placebo",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b4a83d67-2df5-4842-85ba-1f59931925ce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.05,
        "y": 0.86
      },
      "kind": "source-note",
      "text": "1 SVB Securities analyst Marc Goodman\n2 Relyvrio is a registered trademark of Amylyx\n3 Study results are not for comparison",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e46dc72-ba1d-4dca-bf6f-d18b56996c33",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.05,
        "y": 0.06
      },
      "kind": "title",
      "text": "Proven Success of Combined Therapy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce855795-2571-4646-85d3-683b0b448b24",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "authority-citation",
      "slug": null,
      "matchId": "0b78a9af-63df-45ba-b7a2-0c3e6baf8893",
      "evidence": "Citing market cap and FDA approval of a peer company to validate the strategy.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}